A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo |
| |
Authors: | Jones Philip Altamura Sergio De Francesco Raffaele Paz Odalys Gonzalez Kinzel Olaf Mesiti Giuseppe Monteagudo Edith Pescatore Giovanna Rowley Michael Verdirame Maria Steinkühler Christian |
| |
Affiliation: | IRBM/Merck Research Laboratories, Via Pontina km 30,600, 00040 Pomezia, Italy. philip_jones@merck.com |
| |
Abstract: | Histone deacetylase (HDAC) inhibitors offer a promising strategy for cancer therapy, and the first generation HDAC inhibitors are currently in the clinic. Entirely novel ketone HDAC inhibitors have been developed from the cyclic tetrapeptide apicidin. These compounds show class I subtype selectivity and levels of cellular activity comparable to clinical candidates. A representative example has demonstrated tumor growth inhibition in a human colon HCT-116 carcinoma xenograft model comparable to known inhibitors. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|